ZA826031B - New piperazinones,their preparation and their use - Google Patents

New piperazinones,their preparation and their use

Info

Publication number
ZA826031B
ZA826031B ZA826031A ZA826031A ZA826031B ZA 826031 B ZA826031 B ZA 826031B ZA 826031 A ZA826031 A ZA 826031A ZA 826031 A ZA826031 A ZA 826031A ZA 826031 B ZA826031 B ZA 826031B
Authority
ZA
South Africa
Prior art keywords
piperazinones
preparation
new
parenterally
physiologically
Prior art date
Application number
ZA826031A
Other languages
English (en)
Inventor
Rudi Beyerle
Heinz Bender
Ursula Schindler
Rolf Eberhard Nitz
Piero Antonio Martorana
Original Assignee
Cassella Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella Ag filed Critical Cassella Ag
Publication of ZA826031B publication Critical patent/ZA826031B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA826031A 1981-08-20 1982-08-19 New piperazinones,their preparation and their use ZA826031B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813132882 DE3132882A1 (de) 1981-08-20 1981-08-20 Neue piperazinone, ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
ZA826031B true ZA826031B (en) 1983-07-27

Family

ID=6139695

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA826031A ZA826031B (en) 1981-08-20 1982-08-19 New piperazinones,their preparation and their use

Country Status (23)

Country Link
US (1) US4598079A (fr)
EP (1) EP0072932B1 (fr)
JP (1) JPS5839673A (fr)
KR (1) KR880001622B1 (fr)
AT (1) ATE49596T1 (fr)
AU (1) AU556064B2 (fr)
BG (1) BG40142A3 (fr)
CA (1) CA1190227A (fr)
DD (1) DD206991A5 (fr)
DE (2) DE3132882A1 (fr)
DK (1) DK154765C (fr)
ES (1) ES515120A0 (fr)
FI (1) FI76325C (fr)
GR (1) GR78362B (fr)
HU (1) HU190696B (fr)
IL (1) IL66566A (fr)
NO (1) NO822643L (fr)
NZ (1) NZ200761A (fr)
PH (1) PH18447A (fr)
PL (1) PL139405B1 (fr)
PT (1) PT75444B (fr)
RO (1) RO85267B (fr)
ZA (1) ZA826031B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772705A (en) * 1985-07-25 1988-09-20 Pennwalt Corporation Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines
JPS62198671A (ja) * 1986-02-25 1987-09-02 Toyo Jozo Co Ltd １−置換アルキル１，２−ジヒドロ−２−ピラジノン誘導体
DE3817198A1 (de) * 1988-05-20 1989-11-30 Cassella Ag Thienyl-piperazinone, ihre herstellung und verwendung
EP0411150B1 (fr) * 1989-02-10 1996-11-27 Otsuka Pharmaceutical Co., Ltd. Derives d'indole, leur preparation et medicament les contenant destine a la prevention et au traitement de la nephrite
US5238938A (en) * 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
DE3908547A1 (de) * 1989-03-16 1990-09-20 Cassella Ag Thienylessigsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
DE3909379A1 (de) * 1989-03-22 1990-09-27 Cassella Ag Thienylpiperazine, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
DE4408530A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Verfahren zur Herstellung von Aminoethylglycin
DK0777666T3 (da) 1994-08-25 1999-09-27 Merrell Pharma Inc Substituerede piperidiner anvendelige ved behandling af allergiske sygdomme
ATE206421T1 (de) * 1995-03-15 2001-10-15 Aventis Pharma Inc Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
CA2217006C (fr) * 1995-04-13 2001-05-22 Hoechst Marion Roussel, Inc. Nouveaux derives de piperazine substitues presentant une activite d'antagonistes des recepteurs de la tachykinine
GB9510600D0 (en) * 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
WO1997036591A1 (fr) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
IN190478B (fr) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197089B (de) * 1962-01-25 1965-07-22 Richardson Merrell Inc Verfahren zur Herstellung von 2-Oxo-1, 2, 5, 6-tetrahydropyrazinen
US3390139A (en) * 1964-03-04 1966-03-11 Rohm & Haas Nu-vinyl-2-piperazinones
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
DE2438619A1 (de) * 1974-08-12 1976-02-26 Knoll Ag Verfahren zur herstellung von substituierten 2-ketopiperazin-derivaten
AT356122B (de) * 1978-10-17 1980-04-10 Yoshitomi Pharmaceutical Verfahren zur herstellung von neuen pyridazinonderivaten und ihren salzen mit saeuren

Also Published As

Publication number Publication date
FI76325C (fi) 1988-10-10
EP0072932A2 (fr) 1983-03-02
PT75444A (de) 1982-09-01
KR840001158A (ko) 1984-03-28
ES8305739A1 (es) 1983-05-01
DE3280088D1 (de) 1990-02-22
EP0072932B1 (fr) 1990-01-17
DD206991A5 (de) 1984-02-15
NZ200761A (en) 1985-04-30
AU556064B2 (en) 1986-10-23
DK342382A (da) 1983-02-21
AU8742282A (en) 1983-02-24
GR78362B (fr) 1984-09-26
ES515120A0 (es) 1983-05-01
IL66566A (en) 1985-12-31
KR880001622B1 (ko) 1988-09-02
EP0072932A3 (en) 1984-03-21
PT75444B (de) 1985-01-04
NO822643L (no) 1983-02-21
IL66566A0 (en) 1982-12-31
US4598079A (en) 1986-07-01
PH18447A (en) 1985-07-08
RO85267B (ro) 1984-10-30
DK154765C (da) 1989-05-16
CA1190227A (fr) 1985-07-09
BG40142A3 (en) 1986-10-15
FI76325B (fi) 1988-06-30
ATE49596T1 (de) 1990-02-15
PL139405B1 (en) 1987-01-31
FI822698L (fi) 1983-02-21
DE3132882A1 (de) 1983-03-03
HU190696B (en) 1986-10-28
FI822698A0 (fi) 1982-08-02
JPS5839673A (ja) 1983-03-08
DK154765B (da) 1988-12-19
RO85267A (fr) 1984-09-29
PL237952A1 (en) 1983-03-14

Similar Documents

Publication Publication Date Title
PH18447A (en) New piperazinones,their preparation and their use
GB2193641B (en) Penile prosthesis with valving in the cylinder
BR8804837A (pt) Aperfeicoamento em um poco subterraneo,aparelhagem de servico em poco para tratamento de uma formacao produtiva e combinacao
ZA826608B (en) Preparation of water-soluble, nitrogen-containing condensates and their use in papermaking
NO910945L (no) Synergistisk soetemiddelblanding, dens anvendelse i tyggegummi, samt fremgangsmaate for fremstilling av blandingen.
DE3467354D1 (en) Elastomeric copolymers, their preparation and their use
Savage-Smith Hellenistic and Byzantine ophthalmology: Trachoma and sequelae
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
USD275718S (en) Multi-purpose cleaning brush
DE3480095D1 (en) Fibre-reactive chromium complexes, their preparation and their use
EP0142104A3 (en) Fibre-reactive chromium complexes, their preparation and their use
DE3261696D1 (en) Water-soluble polyazo dyestuffs, their preparation and their use
IT8322617V0 (it) Mobili bar, in particolare per uffici e piccole comunita'.
JPS57154470A (en) Synthetic leather excellent in durability and high frequency fusibility
DE3471678D1 (en) Reactive disazo dyes, their preparation and their use
DE3368427D1 (en) Polyphosphates, their preparation and their use
World Health Organization Diarrhoea morbidity, mortality and treatment practices: household survey manual
DE3479426D1 (en) Fibre-reactive chromium complexes, their preparation and their use
West The formation of the Department of Advanced Education: a case study in postsecondary education, 1966-1973
Jaques Organizational factors in the community development process
李小平 Coincidence
ZA916922B (en) Novel cholecystokinin antagonists, their preparation and therapeutic use.
CU21555A1 (en) Antisalmonellosis vaccin by s.dublin and s.typhimurium in calves
Buchanan Sociopsychological climates and affect in adult education classrooms
Chambers Participatory rural appraisal, and whose reality counts?